ADVERTISEMENT
Advertise

Content

List volumes - List articles in this issue

Pruritus in Cutaneous T-cell Lymphomas: Frequent, Often Severe and Difficult to Treat

doi: 10.2340/00015555-0789

Abstract:

Pruritus has a well-known association with Hodgkin’s disease and other nodal lymphomas; indeed it often rev­eals the disease. Pruritus is also an important symptom of cutaneous T-cell lymphomas. Lymphoma-associated itch is thus both frequent and severe, but its pathophysiology remains unclear. Few studies have evaluated the efficacy of therapeutic agents in the management of cutaneous T-cell lymphoma-related pruritus. The main objective of treatment remains disease control. Pruritus management is generally based on the physician’s experience. Treat­ment is very difficult, especially in Sézary syndrome. We present here management strategies for cutaneous lymph­oma-associated pruritus.

Authors:

Nicolas Meyer, Carle Paul, Laurent Misery

References

  • Misery L, Ständer S. Itch. In: Misery L, Ständer S, editors. Pruritus. London: Springer; 2009.
  • Ständer S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 2007; 87: 291–294.
  • Steinhoff M, Bienenstock J, Schmelz M, Maurer M, Wei E, Biro T. Neurophysiological, Neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol 2006; 126: 1705–1718.
  • Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004; 350: 1978–1988.
  • Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113: 5064–5073.
  • Klemke CD, Mansmann U, Poenitz N, Dippel E, Goerdt S. Prognostic factors and prediction of prognosis by the CTCL severity index in mycosis fungoides and sezary syndrome. Br J Dermatol 2005; 153: 118–124.
  • Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768–3785.
  • Demierre MF, Kim YH, Zackheim HS. Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003; 17: 1485–1507.
  • Demierre MF, Tien A, Miller D. Health-related quality of life assessment in patients with cutaneous T-cell lymphoma. Arch Dermatol 2005; 141: 325–330.
  • Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients’ quality of life. Cancer 2006; 107: 2504–2511.
  • Gerami P, Rosen S, Kuzel T, Boone SL, Guitart J. Folliculotropic mycosis fungoides. Arch Dermatol 2008; 144: 738–746.
  • Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31–39.
  • Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjork HE, Handwerker HO. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neurophysiol 2003; 89: 2441–2448.
  • Parker F. Structure and function of skin. In Goldma L, Bennett JC, editors. Cecil Textbook of Medicine. 21st edn. Philadelphia: Saunders; 2000, p. 2266.
  • Krajnik M, Zylicz Z. Understanding pruritus in systemic disease. J Pain Symptom Manage 2001; 21: 151–168.
  • Mc Whorter WP. Allergy and risk of cancer: a prospective study using NHANESI follow up data. Cancer 1988; 62: 451–455.
  • Söderberg KC, Hagmar L, Schwartzbaum J, Feychting M. Allergic conditions and risk of hematological malignancies in adults: a cohort study. BMC Public Health 2004; 4: 51.
  • Eriksson NE, Holmen A, Hogstedt B, Mikoczy Z, Hagmar L. A prospective study of cancer incidenc in a prospective sohort examined for allergy. Allergy 1995; 50: 718–722.
  • Talbot-Smith A, Fritschi L, Divitini ML, Mallon DF, Knuiman MW. Allergy, atopy and cancer: a prospective study of the 1981 Busselton cohort. Am J Epidemiol 2003; 157: 606–612.
  • Cartwright RA, McKinney PA, O’Brien C, Richards ID, Roberts B, Richards ID, et al. Non-Hodgkin’s lymphoma: case-control epidemiological study in Yorkshire. Leuk Res 1988; 12: 81–88.
  • Mehrany K, El-Azhary RA, Bouwhuis SA, Pittelkow MR. Cutaneous T-cell lymphoma and atopy: is there an association? Br J Dermatol 2003; 149: 1013–1017.
  • Meyer N, Mazereeuw-Hautier J, Launay F, Lamant L, Paul C. Cutaneous T cell lymphoma complicating severe atopic dermatitis. Is making a diagnosis the main challenge? Dermatology 2009; 218: 168–171.
  • Rubegni P, De Aloe G, Di Renzo M, Pompella G, Pasqui AL, Auteri A, et al. Cytokine production profile of peripheral blood mononuclear cells in patients with large-plaque parapsoriasis. Arch Dermatol 2001; 137: 966–967.
  • Dummer R, Heald PW, Nestle FO, Ludwig E, Laine E, Hemmi S, et al. Sezary syndrome T-cells clones display T-helper2 cytokines and express the accessory factor-1 (interferon gamma receptor beta-chain). Blood 1996; 88: 1383–1389.
  • Wahlgren CF, Tengvall Linder M, Hägermark O, Scheynius A. Itch and inflammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects. Arch Dermatol Res 1995; 287: 572–580.
  • Darsow U, Scharein E, Bromm B, Ring J. Skin Testing of the pruritogenic activity of histamine and cytokines (interleukin 2 and tumour necrosis factor-alpha) at the dermal epidermal junction. Br J Dermatol 1997; 137: 415–417.
  • Kimmel M, Alscher DM, Dunst R, Braun N, Machleidt C, Kiefer T, et al. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant 2006; 21: 749–755.
  • Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006; 117: 411–417.
  • Rich BE, Campos-Torres J, Tepper RI, Moreadith RW, Leder P. Cutaneous Lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exp Med 1993; 177: 305–316.
  • Heufler C, Topar G, Grasseger A, Stanzl U, Koch F, Romani N, et al. Interleukin 7 is produced by murine and human keratinocytes. J Exp Med 1993; 178: 1109–1114.
  • Dalloul A, Laroche L, Bagot M, Mossalayi MD, Fourcade C, Thacker DJ, et al. Interleukin-7 is a growth factor for Sezary lymphoma cells. J Clin Invest 1992; 90: 1054.
  • Shellow WV. Evaluation of pruritus. In Goroll AH, Mulley AG Jr, editors. Primary care medicine: office evaluation and management of the adult patient. 4th edn. Philadelphia: Lippincott Williams & Wilkins; 2000, p. 1001–1004.
  • Yamamoto T, Katayama I, Nishioka N. Role of mast cell and stem cell factor in hyperpigmented mycosis fungoides. Blood 1997; 90: 1338–1340.
  • Brandes LJ, La Bella FS, Warrington FC. Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonist. J Natl Cancer Inst 1991; 83: 1329–1336.
  • Vermeer MH, Willemze R. Is Mycosis Fungoides exacerbated by fluoxetine? J Am Acad Dermatol 1996; 35: 635–636.
  • Magro CM, Crowson AN. Drugs with antihistaminic properties as a cause of atypical cutaneous lymphoid hyperplasia. J Am Acad Dermatol 1995; 32: 419–428.
  • Meyer-Hoffert U. Reddish, scaly, and itchy: how proteases and their inhibitors contribute to inflammatory skin diseases. Arch Immunol Ther Exp 2009; 57: 345–354.
  • Moses S. Pruritus. Am Fam Physician 2003; 68: 1135–1142, 1145–1146.
  • Namaka M, Gramlich CR, Ruhlen D, Melanson M, Sutton I, Major J. A treatment algorithm for neuropathic pain. Clin Ther 2004; 26: 951–979.
  • Elmer KB, George RM. Cutaneous T-cell lymphoma presenting as benign dermatoses. Am Fam Physician 1999; 59: 2809–2813.
  • D’incan M. Souteyran P. Mycosis fongoïde et formes apparentées. In: Saurat JH, Lachapelle JM, Lipsker D, Thomas L, editors. Dermatologie et infections sexuellement transmissibles, 5e édition. Paris: Masson; 2008.
  • Hope RT, Wood GS, Abel EA. Mycosis fungoides and the Sezary syndrome: pathology, staging, and treatment. Curr Probl Cancer 1990; 14: 293–371.
  • Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol 1998; 134: 949–954.
  • Zackheim HS. Treatment of mycosis fungoides/Sezary syndrome: the University of California, San Francisco (UCSF) approach. Int J Dermatol 2003; 4: 53–56.
  • Yosipovitch G, Szolar C, Hui XY, Maibach H. High-potency topical corticosteroid rapidly decrease histamine-induced itch but not thermal sensation and pain in human beings. J Am Acad Dermatol 1996; 35: 118–120.
  • Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006; 42: 1014–1030.
  • Bingham LG, Noble JW, Davis MD. Wet dressing used with topical corticosteroids for pruritic dermatoses: a sretrospective study. J Am Acad Dermatol 2009; 60: 792–800.
  • Brune A, Metze D, Luger TA, Ständer S. Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non placebo controlled administration in 133 patients. Hautarzt 2004; 55: 1130–1136.
  • Baron ED, Stevens SR. Phototherapy for cutaneous T-cell lymphoma. Dermatol Ther 2003; 16: 303–310.
  • Zackheim HS, Kashani-Sabet M, McMillan A. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol 2003; 49: 873–878.
  • Gamblicher T, Breuckmann F, Boms S, Altmeyer P, Kreuter A. Narrowband phototherapy in skin conditions beyond psoriasis. J Am Acad Dermatol 2005; 52: 660–670.
  • Mostow E, Neckel S, Oberhelman L, Anderson T. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alpha and PUVA. Arch Dermatol 1993; 129: 747–752.
  • Papadavid E, Antoniou C, Nikolaou V, Siakantaris M, Vassilakopolous TP, Stratigos A, et al. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides. Am J Clin Dermatol 2008; 9: 169–173.
  • Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol 2007; 157: 433–440.
  • Rivard J, Henry WL. Ultraviolet phototherapy for pruritus. Dermatol Ther 2005; 18: 344–354.
  • Yashar SS, Gielczyk R, Scherschun L, Lim HW. Narrow-band ultraviolet B for vitiligo, pruritus, and inflammatory dermatoses. Photodermatol Photoimmunol Photomed 2003; 19: 164–168.
  • Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, et al. Quality of life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clin Lymphoma 2002; 43: 121–126.
  • Olsen EA, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376–388.
  • Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003; 101: 4267–4272.
  • Brightman L, Demierre MF. Thalidomide in mycosis fungoides. J Am Acad Dermatol 2005; 52: 1100–1101.
  • Summey BT, Yosipovitch G. Pharmacologic advances in the systemic treatment of itch. Dermatol Ther 2005; 18: 328–332.
  • Yosipovitch G, Fleischer A. Itch associated with skin diseases: advances in pathophysiology and emerging therapies. Am J Clin Dermatol 2003; 4: 617–622.
  • Zackheim HS, Kashani-Sabet M, Hwang ST. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 1996; 34: 626–631.
  • Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol 2006; 55: 543–544.
  • Bigata X, Sais G, Soler F. Severe chronic urticaria: response to mirtazapine. J Am Acad Dermatol 2005; 53: 916–917.
  • Yesudian PD, Wilson NJE. Efficacy of gabapentin in the management of pruritus of unkown origin. Arch Dermatol 2005; 141: 1507–1509.
  • Sepmeyer JA, Greer JP, Koyama T, Zic JA. Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell Lymphoma. J Am Acad Dermatol 2007; 56: 584–587.
  • Martin PG, Lasserre F, Calleja C, Van Es A, Roulet A, Concordet D, et al. Transcriptional modulations by RXR agonists are only partially subordinated to PPARalpha signaling and attest additional, organ-specific, molecular cross-talks. Gene Expr 2005; 12: 177–192.
  • Zic JA. The treatment of cutaneous T-Cell lymphoma with photopheresis. Dermatol Ther 2003; 16: 337–346.
  • Zic JA, Stricklin GP, Greer JP, Kinney MC, Shyr Y, Wilson DC, King LE Jr. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 1996; 35: 935–945
  • Scarisbrick JJ, Taylor P, Holtick U, Makar Y, Douglas K, Berlin G, et al. Photopheresis expert group. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol 2008; 158: 659–678.
  • Bouwhuis SA, McEvoy MT, Davis MD. Sustained remission of Sezary syndrome. Eur J Dermatol 2002; 12: 287–290.
  • Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Engl J Med 2009; 361: 1415–1416.

    • Share with your friends





    Actions


    Abstract

    Full text

    PDF

    Supplementary


    There is no supplementary for this article.

    Print information


    Volume 90, Issue 1

    DOI: 10.2340/00015555-0789

    Pages: 12-17

    View at PubMed